Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Corneal Crosslinking Clear all
Recruiting Phase 2Phase 3 Interventional

Comparison of Standard vs. Accelerated Corneal Crosslinking

NCT03922542
View directory record Official record
Conditions
Keratoconus, Ectasia Corneal
Interventions
Riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
10 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

McNeel Eye Center Corneal Crosslinking Study

NCT02921009
View directory record Official record
Conditions
Keratoconus
Interventions
Crosslinking using UV light of two different fluence rates
Device
Lead sponsor
McNeel Eye Center
Industry
Eligibility
15 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus

NCT01672814
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin ophthalmic solution, Vedera KXS Microwave System
Drug · Device
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin

NCT01152541
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin/Dextran, Hypotonic Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Epi-On Corneal Crosslinking for Keratoconus

NCT03245853
View directory record Official record
Conditions
Keratoconus, Keratoconus, Unstable
Interventions
Riboflavin 5'-Phosphate
Drug
Lead sponsor
Comprehensive EyeCare of Central Ohio
Other
Eligibility
14 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional

Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia

NCT01464268
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

NCT01112072
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose

NCT04897503
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
12 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jun 10, 2026, 1:27 PM EDT
Not yet recruiting Not applicable Interventional

A Randomized Clinical Trial of Ex Vivo Corneal Cross-Linking of Donor Keratoplasty Tissue for Keratoconus Used for Keratoplasty in Keratoconus Patients

NCT04584125
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light, Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Recruiting Phase 3 Interventional

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

NCT07135167
View directory record Official record
Conditions
Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions
Epi-ON corneal cross-linking (CXL)
Combination Product
Lead sponsor
Woolfson Eye Institute
Other
Eligibility
8 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated No phase listed Observational

Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas

NCT01189864
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicin or Vigamox or other., Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
12 Years and older
Enrollment
3,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
16
States / cities
Scottsdale, Arizona • Laguna Hills, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated Phase 2 Interventional

CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01956474
View directory record Official record
Conditions
Keratoconus
Interventions
Theralight crosslinking and Riboflavin
Other
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Miami, Florida • Atlanta, Georgia • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")

NCT03938883
View directory record Official record
Conditions
Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
Interventions
Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
Device
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
22 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of OBG vs.a Bandage Contact Lens for Large Corneal Epithelial Defects in Patients Post-PRK.

NCT03163641
View directory record Official record
Conditions
Corneal Epithelial Wound
Interventions
Acuvue Oasys, Ocular Bandage Gel
Device
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
22 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Corneal Crosslinking Using the PXL-Platinum 330 for Eyes With Corneal Ectatic Conditions

NCT04240457
View directory record Official record
Conditions
Keratoconus, Cornea Ectasia
Interventions
Epithelial-on Corneal Crosslinking with the PXL 330 Platinum system.
Combination Product
Lead sponsor
Arbor Center for Eye Care
Other
Eligibility
12 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orland Park, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 10, 2026, 1:27 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking

NCT06235567
View directory record Official record
Conditions
Keratoconus
Interventions
Dextenza 0.4Mg Ophthalmic Insert, topical prednisolone acetate 1% (PredForte) eye drops
Drug
Lead sponsor
Maanasa Indaram, MD
Other
Eligibility
13 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jun 10, 2026, 1:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System

NCT05423041
View directory record Official record
Conditions
Corneal Transplant, Corneal Crosslinking, Healthy Eyes
Interventions
BOSS Imaging
Diagnostic Test
Lead sponsor
Intelon Optics, Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

NCT05136924
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
Drug · Other
Lead sponsor
Vance Thompson Vision - MT
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jun 10, 2026, 1:27 PM EDT
Terminated No phase listed Observational

Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas

NCT01024322
View directory record Official record
Conditions
Keratoconus, Ectasia, Degeneration
Interventions
Ciprofloxicine or Vigamox or other., Nonsteroidal (Acular, Voltaren Xibrom, etc), Steroid (FML, Pred Forte, Flarex, etc.)
Drug
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Miami, Florida • Rockville, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

NCT03080077
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, Epi-Off
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jun 10, 2026, 1:27 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
riboflavin ophthalmic solution
Drug
Lead sponsor
Cornea and Laser Eye Institute
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jun 10, 2026, 1:27 PM EDT